Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data

ConclusionConcizumab phase 2 trials will target an exposure ≥100 ng/mL, with a once‐daily regimen.

Source: Haemophilia - November 8, 2018 Category: Hematology Authors: Hermann Eichler, Pantep Angchaisuksiri, Kaan Kavakli, Paul Knoebl, Jerzy Windyga, Victor Jim énez‐Yuste, Philip Harder Delff, Pratima Chowdary Tags: ORIGINAL ARTICLE Source Type: research